BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 32532514)

  • 21. Targeted prostate cancer screening in men with mutations in BRCA1 and BRCA2 detects aggressive prostate cancer: preliminary analysis of the results of the IMPACT study.
    Mitra AV; Bancroft EK; Barbachano Y; Page EC; Foster CS; Jameson C; Mitchell G; Lindeman GJ; Stapleton A; Suthers G; Evans DG; Cruger D; Blanco I; Mercer C; Kirk J; Maehle L; Hodgson S; Walker L; Izatt L; Douglas F; Tucker K; Dorkins H; Clowes V; Male A; Donaldson A; Brewer C; Doherty R; Bulman B; Osther PJ; Salinas M; Eccles D; Axcrona K; Jobson I; Newcombe B; Cybulski C; Rubinstein WS; Buys S; Townshend S; Friedman E; Domchek S; Ramon Y Cajal T; Spigelman A; Teo SH; Nicolai N; Aaronson N; Ardern-Jones A; Bangma C; Dearnaley D; Eyfjord J; Falconer A; Grönberg H; Hamdy F; Johannsson O; Khoo V; Kote-Jarai Z; Lilja H; Lubinski J; Melia J; Moynihan C; Peock S; Rennert G; Schröder F; Sibley P; Suri M; Wilson P; Bignon YJ; Strom S; Tischkowitz M; Liljegren A; Ilencikova D; Abele A; Kyriacou K; van Asperen C; Kiemeney L; ; Easton DF; Eeles RA
    BJU Int; 2011 Jan; 107(1):28-39. PubMed ID: 20840664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study.
    Segev Y; Iqbal J; Lubinski J; Gronwald J; Lynch HT; Moller P; Ghadirian P; Rosen B; Tung N; Kim-Sing C; Foulkes WD; Neuhausen SL; Senter L; Singer CF; Karlan B; Ping S; Narod SA;
    Gynecol Oncol; 2013 Jul; 130(1):127-31. PubMed ID: 23562522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum testosterone and prostate cancer in men with germline
    Dias A; Brook MN; Bancroft EK; Page EC; Chamberlain A; Saya S; Amin J; Mikropoulos C; Taylor N; Myhill K; Thomas S; Saunders E; Dadaev T; Leongamornlert D; Dyrsø Jensen T; Evans DG; Cybulski C; Liljegren A; Teo SH; Side L; ; Kote-Jarai Z; Eeles RA
    BJUI Compass; 2023 May; 4(3):361-373. PubMed ID: 37025481
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Absence of 185delAG mutation of the BRCA1 gene and 6174delT mutation of the BRCA2 gene in Ashkenazi Jewish men with prostate cancer.
    Lehrer S; Fodor F; Stock RG; Stone NN; Eng C; Song HK; McGovern M
    Br J Cancer; 1998 Sep; 78(6):771-3. PubMed ID: 9743298
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Risk-reducing bilateral salpingo-oophorectomy in women with BRCA1 or BRCA2 mutations.
    Eleje GU; Eke AC; Ezebialu IU; Ikechebelu JI; Ugwu EO; Okonkwo OO
    Cochrane Database Syst Rev; 2018 Aug; 8(8):CD012464. PubMed ID: 30141832
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated expression of Ki-67 identifies aggressive prostate cancers but does not distinguish BRCA1 or BRCA2 mutation carriers.
    Mitra AV; Jameson C; Barbachano Y; Sodha N; Kote-Jarai Z; Javed A; Bancroft E; Fletcher A; Cooper C; Peock S; ; Easton D; Eeles R; Foster CS
    Oncol Rep; 2010 Feb; 23(2):299-305. PubMed ID: 20043088
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer.
    Rebbeck TR; Mitra N; Wan F; Sinilnikova OM; Healey S; McGuffog L; Mazoyer S; Chenevix-Trench G; Easton DF; Antoniou AC; Nathanson KL; ; Laitman Y; Kushnir A; Paluch-Shimon S; Berger R; Zidan J; Friedman E; Ehrencrona H; Stenmark-Askmalm M; Einbeigi Z; Loman N; Harbst K; Rantala J; Melin B; Huo D; Olopade OI; Seldon J; Ganz PA; Nussbaum RL; Chan SB; Odunsi K; Gayther SA; Domchek SM; Arun BK; Lu KH; Mitchell G; Karlan BY; Walsh C; Lester J; Godwin AK; Pathak H; Ross E; Daly MB; Whittemore AS; John EM; Miron A; Terry MB; Chung WK; Goldgar DE; Buys SS; Janavicius R; Tihomirova L; Tung N; Dorfling CM; van Rensburg EJ; Steele L; Neuhausen SL; Ding YC; Ejlertsen B; Gerdes AM; Hansen Tv; Ramón y Cajal T; Osorio A; Benitez J; Godino J; Tejada MI; Duran M; Weitzel JN; Bobolis KA; Sand SR; Fontaine A; Savarese A; Pasini B; Peissel B; Bonanni B; Zaffaroni D; Vignolo-Lutati F; Scuvera G; Giannini G; Bernard L; Genuardi M; Radice P; Dolcetti R; Manoukian S; Pensotti V; Gismondi V; Yannoukakos D; Fostira F; Garber J; Torres D; Rashid MU; Hamann U; Peock S; Frost D; Platte R; Evans DG; Eeles R; Davidson R; Eccles D; Cole T; Cook J; Brewer C; Hodgson S; Morrison PJ; Walker L; Porteous ME; Kennedy MJ; Izatt L; Adlard J; Donaldson A; Ellis S; Sharma P; Schmutzler RK; Wappenschmidt B; Becker A; Rhiem K; Hahnen E; Engel C; Meindl A; Engert S; Ditsch N; Arnold N; Plendl HJ; Mundhenke C; Niederacher D; Fleisch M; Sutter C; Bartram CR; Dikow N; Wang-Gohrke S; Gadzicki D; Steinemann D; Kast K; Beer M; Varon-Mateeva R; Gehrig A; Weber BH; Stoppa-Lyonnet D; Sinilnikova OM; Mazoyer S; Houdayer C; Belotti M; Gauthier-Villars M; Damiola F; Boutry-Kryza N; Lasset C; Sobol H; Peyrat JP; Muller D; Fricker JP; Collonge-Rame MA; Mortemousque I; Nogues C; Rouleau E; Isaacs C; De Paepe A; Poppe B; Claes K; De Leeneer K; Piedmonte M; Rodriguez G; Wakely K; Boggess J; Blank SV; Basil J; Azodi M; Phillips KA; Caldes T; de la Hoya M; Romero A; Nevanlinna H; Aittomäki K; van der Hout AH; Hogervorst FB; Verhoef S; Collée JM; Seynaeve C; Oosterwijk JC; Gille JJ; Wijnen JT; Gómez Garcia EB; Kets CM; Ausems MG; Aalfs CM; Devilee P; Mensenkamp AR; Kwong A; Olah E; Papp J; Diez O; Lazaro C; Darder E; Blanco I; Salinas M; Jakubowska A; Lubinski J; Gronwald J; Jaworska-Bieniek K; Durda K; Sukiennicki G; Huzarski T; Byrski T; Cybulski C; Toloczko-Grabarek A; Złowocka-Perłowska E; Menkiszak J; Arason A; Barkardottir RB; Simard J; Laframboise R; Montagna M; Agata S; Alducci E; Peixoto A; Teixeira MR; Spurdle AB; Lee MH; Park SK; Kim SW; Friebel TM; Couch FJ; Lindor NM; Pankratz VS; Guidugli L; Wang X; Tischkowitz M; Foretova L; Vijai J; Offit K; Robson M; Rau-Murthy R; Kauff N; Fink-Retter A; Singer CF; Rappaport C; Gschwantler-Kaulich D; Pfeiler G; Tea MK; Berger A; Greene MH; Mai PL; Imyanitov EN; Toland AE; Senter L; Bojesen A; Pedersen IS; Skytte AB; Sunde L; Thomassen M; Moeller ST; Kruse TA; Jensen UB; Caligo MA; Aretini P; Teo SH; Selkirk CG; Hulick PJ; Andrulis I
    JAMA; 2015 Apr; 313(13):1347-61. PubMed ID: 25849179
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer.
    Carter HB; Helfand B; Mamawala M; Wu Y; Landis P; Yu H; Wiley K; Na R; Shi Z; Petkewicz J; Shah S; Fantus RJ; Novakovic K; Brendler CB; Zheng SL; Isaacs WB; Xu J
    Eur Urol; 2019 May; 75(5):743-749. PubMed ID: 30309687
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.
    Na R; Zheng SL; Han M; Yu H; Jiang D; Shah S; Ewing CM; Zhang L; Novakovic K; Petkewicz J; Gulukota K; Helseth DL; Quinn M; Humphries E; Wiley KE; Isaacs SD; Wu Y; Liu X; Zhang N; Wang CH; Khandekar J; Hulick PJ; Shevrin DH; Cooney KA; Shen Z; Partin AW; Carter HB; Carducci MA; Eisenberger MA; Denmeade SR; McGuire M; Walsh PC; Helfand BT; Brendler CB; Ding Q; Xu J; Isaacs WB
    Eur Urol; 2017 May; 71(5):740-747. PubMed ID: 27989354
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased Risk of Hereditary Prostate Cancer in Italian Families with Hereditary Breast and Ovarian Cancer Syndrome Harboring Mutations in
    D'Elia G; Caliendo G; Tzioni MM; Albanese L; Passariello L; Molinari AM; Vietri MT
    Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292577
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Germline genetic testing for inherited prostate cancer in practice: Implications for genetic testing, precision therapy, and cascade testing.
    Giri VN; Hegarty SE; Hyatt C; O'Leary E; Garcia J; Knudsen KE; Kelly WK; Gomella LG
    Prostate; 2019 Mar; 79(4):333-339. PubMed ID: 30450585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Homeobox B13 G84E Mutation and Prostate Cancer Risk.
    Nyberg T; Govindasami K; Leslie G; Dadaev T; Bancroft E; Ni Raghallaigh H; Brook MN; Hussain N; Keating D; Lee A; McMahon R; Morgan A; Mullen A; Osborne A; Rageevakumar R; ; Kote-Jarai Z; Eeles R; Antoniou AC
    Eur Urol; 2019 May; 75(5):834-845. PubMed ID: 30527799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. BRCA2 mutations should be screened early and routinely as markers of poor prognosis: evidence from 8,988 patients with prostate cancer.
    Cui M; Gao XS; Gu X; Guo W; Li X; Ma M; Qin S; Qi X; Xie M; Peng C; Bai Y
    Oncotarget; 2017 Jun; 8(25):40222-40232. PubMed ID: 28410213
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Impact of germline BRCA2 and CHEK2 mutations on time to castration resistance in patients with metastatic hormone-nave prostate cancer].
    Matveev VB; Kirichek AA; Filippova MG; Savinkova AV; Khalmurzaev OA; Lyubchenko LN
    Urologiia; 2019 Dec; (5):79-85. PubMed ID: 31808637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Male BRCA1 and BRCA2 mutation carriers: a pilot study investigating medical characteristics of patients participating in a prostate cancer prevention clinic.
    Horsburgh S; Matthew A; Bristow R; Trachtenberg J
    Prostate; 2005 Oct; 65(2):124-9. PubMed ID: 15880530
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective study of breast cancer risk for mutation negative women from BRCA1 or BRCA2 mutation positive families.
    Harvey SL; Milne RL; McLachlan SA; Friedlander ML; Birch KE; Weideman P; ; Goldgar D; Hopper JL; Phillips KA
    Breast Cancer Res Treat; 2011 Dec; 130(3):1057-61. PubMed ID: 21850394
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
    Mavaddat N; Peock S; Frost D; Ellis S; Platte R; Fineberg E; Evans DG; Izatt L; Eeles RA; Adlard J; Davidson R; Eccles D; Cole T; Cook J; Brewer C; Tischkowitz M; Douglas F; Hodgson S; Walker L; Porteous ME; Morrison PJ; Side LE; Kennedy MJ; Houghton C; Donaldson A; Rogers MT; Dorkins H; Miedzybrodzka Z; Gregory H; Eason J; Barwell J; McCann E; Murray A; Antoniou AC; Easton DF;
    J Natl Cancer Inst; 2013 Jun; 105(11):812-22. PubMed ID: 23628597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imaging-based prostate cancer screening among BRCA mutation carriers-results from the first round of screening.
    Segal N; Ber Y; Benjaminov O; Tamir S; Yakimov M; Kedar I; Rosenbaum E; Sela S; Ozalvo R; Shavit-Grievink L; Keder D; Baniel J; Margel D
    Ann Oncol; 2020 Nov; 31(11):1545-1552. PubMed ID: 32958357
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breast cancer risk among male BRCA1 and BRCA2 mutation carriers.
    Tai YC; Domchek S; Parmigiani G; Chen S
    J Natl Cancer Inst; 2007 Dec; 99(23):1811-4. PubMed ID: 18042939
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA mutations and risk of prostate cancer in Ashkenazi Jews.
    Kirchhoff T; Kauff ND; Mitra N; Nafa K; Huang H; Palmer C; Gulati T; Wadsworth E; Donat S; Robson ME; Ellis NA; Offit K
    Clin Cancer Res; 2004 May; 10(9):2918-21. PubMed ID: 15131025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.